Cargando…
MICU1 drives glycolysis and chemoresistance in ovarian cancer
Cancer cells actively promote aerobic glycolysis to sustain their metabolic requirements through mechanisms not always clear. Here, we demonstrate that the gatekeeper of mitochondrial Ca(2+) uptake, Mitochondrial Calcium Uptake 1 (MICU1/CBARA1) drives aerobic glycolysis in ovarian cancer. We show th...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477507/ https://www.ncbi.nlm.nih.gov/pubmed/28530221 http://dx.doi.org/10.1038/ncomms14634 |
_version_ | 1783244807566524416 |
---|---|
author | Chakraborty, Prabir K. Mustafi, Soumyajit Banerjee Xiong, Xunhao Dwivedi, Shailendra Kumar Dhar Nesin, Vasyl Saha, Sounik Zhang, Min Dhanasekaran, Danny Jayaraman, Muralidharan Mannel, Robert Moore, Kathleen McMeekin, Scott Yang, Da Zuna, Rosemary Ding, Kai Tsiokas, Leonidas Bhattacharya, Resham Mukherjee, Priyabrata |
author_facet | Chakraborty, Prabir K. Mustafi, Soumyajit Banerjee Xiong, Xunhao Dwivedi, Shailendra Kumar Dhar Nesin, Vasyl Saha, Sounik Zhang, Min Dhanasekaran, Danny Jayaraman, Muralidharan Mannel, Robert Moore, Kathleen McMeekin, Scott Yang, Da Zuna, Rosemary Ding, Kai Tsiokas, Leonidas Bhattacharya, Resham Mukherjee, Priyabrata |
author_sort | Chakraborty, Prabir K. |
collection | PubMed |
description | Cancer cells actively promote aerobic glycolysis to sustain their metabolic requirements through mechanisms not always clear. Here, we demonstrate that the gatekeeper of mitochondrial Ca(2+) uptake, Mitochondrial Calcium Uptake 1 (MICU1/CBARA1) drives aerobic glycolysis in ovarian cancer. We show that MICU1 is overexpressed in a panel of ovarian cancer cell lines and that MICU1 overexpression correlates with poor overall survival (OS). Silencing MICU1 in vitro increases oxygen consumption, decreases lactate production, inhibits clonal growth, migration and invasion of ovarian cancer cells, whereas silencing in vivo inhibits tumour growth, increases cisplatin efficacy and OS. Mechanistically, silencing MICU1 activates pyruvate dehydrogenase (PDH) by stimulating the PDPhosphatase-phosphoPDH-PDH axis. Forced-expression of MICU1 in normal cells phenocopies the metabolic aberrations of malignant cells. Consistent with the in vitro and in vivo findings we observe a significant correlation between MICU1 and pPDH (inactive form of PDH) expression with poor prognosis. Thus, MICU1 could serve as an important therapeutic target to normalize metabolic aberrations responsible for poor prognosis in ovarian cancer. |
format | Online Article Text |
id | pubmed-5477507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-54775072017-07-03 MICU1 drives glycolysis and chemoresistance in ovarian cancer Chakraborty, Prabir K. Mustafi, Soumyajit Banerjee Xiong, Xunhao Dwivedi, Shailendra Kumar Dhar Nesin, Vasyl Saha, Sounik Zhang, Min Dhanasekaran, Danny Jayaraman, Muralidharan Mannel, Robert Moore, Kathleen McMeekin, Scott Yang, Da Zuna, Rosemary Ding, Kai Tsiokas, Leonidas Bhattacharya, Resham Mukherjee, Priyabrata Nat Commun Article Cancer cells actively promote aerobic glycolysis to sustain their metabolic requirements through mechanisms not always clear. Here, we demonstrate that the gatekeeper of mitochondrial Ca(2+) uptake, Mitochondrial Calcium Uptake 1 (MICU1/CBARA1) drives aerobic glycolysis in ovarian cancer. We show that MICU1 is overexpressed in a panel of ovarian cancer cell lines and that MICU1 overexpression correlates with poor overall survival (OS). Silencing MICU1 in vitro increases oxygen consumption, decreases lactate production, inhibits clonal growth, migration and invasion of ovarian cancer cells, whereas silencing in vivo inhibits tumour growth, increases cisplatin efficacy and OS. Mechanistically, silencing MICU1 activates pyruvate dehydrogenase (PDH) by stimulating the PDPhosphatase-phosphoPDH-PDH axis. Forced-expression of MICU1 in normal cells phenocopies the metabolic aberrations of malignant cells. Consistent with the in vitro and in vivo findings we observe a significant correlation between MICU1 and pPDH (inactive form of PDH) expression with poor prognosis. Thus, MICU1 could serve as an important therapeutic target to normalize metabolic aberrations responsible for poor prognosis in ovarian cancer. Nature Publishing Group 2017-05-22 /pmc/articles/PMC5477507/ /pubmed/28530221 http://dx.doi.org/10.1038/ncomms14634 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Chakraborty, Prabir K. Mustafi, Soumyajit Banerjee Xiong, Xunhao Dwivedi, Shailendra Kumar Dhar Nesin, Vasyl Saha, Sounik Zhang, Min Dhanasekaran, Danny Jayaraman, Muralidharan Mannel, Robert Moore, Kathleen McMeekin, Scott Yang, Da Zuna, Rosemary Ding, Kai Tsiokas, Leonidas Bhattacharya, Resham Mukherjee, Priyabrata MICU1 drives glycolysis and chemoresistance in ovarian cancer |
title | MICU1 drives glycolysis and chemoresistance in ovarian cancer |
title_full | MICU1 drives glycolysis and chemoresistance in ovarian cancer |
title_fullStr | MICU1 drives glycolysis and chemoresistance in ovarian cancer |
title_full_unstemmed | MICU1 drives glycolysis and chemoresistance in ovarian cancer |
title_short | MICU1 drives glycolysis and chemoresistance in ovarian cancer |
title_sort | micu1 drives glycolysis and chemoresistance in ovarian cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477507/ https://www.ncbi.nlm.nih.gov/pubmed/28530221 http://dx.doi.org/10.1038/ncomms14634 |
work_keys_str_mv | AT chakrabortyprabirk micu1drivesglycolysisandchemoresistanceinovariancancer AT mustafisoumyajitbanerjee micu1drivesglycolysisandchemoresistanceinovariancancer AT xiongxunhao micu1drivesglycolysisandchemoresistanceinovariancancer AT dwivedishailendrakumardhar micu1drivesglycolysisandchemoresistanceinovariancancer AT nesinvasyl micu1drivesglycolysisandchemoresistanceinovariancancer AT sahasounik micu1drivesglycolysisandchemoresistanceinovariancancer AT zhangmin micu1drivesglycolysisandchemoresistanceinovariancancer AT dhanasekarandanny micu1drivesglycolysisandchemoresistanceinovariancancer AT jayaramanmuralidharan micu1drivesglycolysisandchemoresistanceinovariancancer AT mannelrobert micu1drivesglycolysisandchemoresistanceinovariancancer AT moorekathleen micu1drivesglycolysisandchemoresistanceinovariancancer AT mcmeekinscott micu1drivesglycolysisandchemoresistanceinovariancancer AT yangda micu1drivesglycolysisandchemoresistanceinovariancancer AT zunarosemary micu1drivesglycolysisandchemoresistanceinovariancancer AT dingkai micu1drivesglycolysisandchemoresistanceinovariancancer AT tsiokasleonidas micu1drivesglycolysisandchemoresistanceinovariancancer AT bhattacharyaresham micu1drivesglycolysisandchemoresistanceinovariancancer AT mukherjeepriyabrata micu1drivesglycolysisandchemoresistanceinovariancancer |